Sercloremine

Sercloremine (also known as CGP-4718A) is a monoamine oxidase inhibitor (MAOI) and antidepressant that was developed but never marketed. It is selective for monoamine oxidase B (MAO-B) over monoamine oxidase A (MAO-A).

Pharmacology

Sercloremine is a selective inhibitor of MAO-B, which means it preferentially inhibits this subtype of monoamine oxidase. MAO-B is responsible for the breakdown of dopamine in the brain, so inhibiting this enzyme can increase dopamine levels. This can have a variety of effects, including improving mood and reducing symptoms of Parkinson's disease.

Development and Marketing

Sercloremine was developed by the pharmaceutical company Ciba-Geigy, but it was never marketed. The reasons for this are not clear, but it may have been due to concerns about the safety and efficacy of MAOIs in general.

See Also

• Monoamine oxidase inhibitor
• Antidepressant
• Ciba-Geigy

References

Sercloremine Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski